Adaptimmune Therapeutics plc - American Depositary Shares (ADAP) Got Lower SVB Leerink Rating; National General Holdings Corp. (NGHC) Sentiment Is 1.93

National General Holdings Corp. (NASDAQ:NGHC) Logo

In a analysts report issued to investors and clients on Tuesday morning, SVB Leerink has decreased Adaptimmune Therapeutics plc - American Depositary Shares (NASDAQ:ADAP) stock to “Market Perform”. ADAP’s old rating was “Outperform”.

National General Holdings Corp. (NGHC) investors sentiment increased to 1.93 in Q4 2018. It’s up 0.98, from 0.95 in 2018Q3. The ratio improved, as 89 active investment managers opened new and increased stock positions, while 46 trimmed and sold equity positions in National General Holdings Corp.. The active investment managers in our database now hold: 54.04 million shares, up from 47.91 million shares in 2018Q3. Also, the number of active investment managers holding National General Holdings Corp. in top ten stock positions increased from 3 to 4 for an increase of 1. Sold All: 10 Reduced: 36 Increased: 55 New Position: 34.

The stock increased 5.26% or $0.23 during the last trading session, reaching $4.6. About 483,127 shares traded or 57.59% up from the average. Adaptimmune Therapeutics plc (NASDAQ:ADAP) has declined 46.89% since May 7, 2018 and is downtrending. It has underperformed by 51.26% the S&P500. Some Historical ADAP News: 15/03/2018 - Adaptimmune Therapeutics 4Q Loss/Shr 5c; 09/05/2018 - Adaptimmune Therapeutics 1Q Loss/Shr 4c; 15/03/2018 - Adaptimmune Therapeutics: Data Provides Confirmation of Broad Applicability of SPEAR TCR T-cell Platform in Solid Tumors; 15/03/2018 - ADAPTIMMUNE THERAPEUTICS - REPORTED 3 PARTIAL RESPONSES & 1 STABLE DISEASE IN FIRST 4 PATIENTS DOSED WITH NY-ESO SPEAR T-CELLS IN A SECOND SOLID TUMOR; 13/03/2018 Investor Expectations to Drive Momentum within Methanex, YPF Sociedad Anonima, Adaptimmune Therapeutics, Horizon Pharma, Changy; 15/03/2018 - ADAPTIMMUNE THERAPEUTICS - TRANSITION OF NY-ESO SPEAR T-CELL THERAPY PROGRAM IS ONGOING GLAXOSMITHKLINE PLC; 15/03/2018 - ADAPTIMMUNE REPORTS RESPONSES IN SECOND SOLID TUMOR INDICATION; 15/03/2018 - Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells; 09/05/2018 - ADAPTIMMUNE THERAPEUTICS PLC - GUIDANCE CONFIRMED, FUNDED THROUGH TO EARLY 2020; 16/04/2018 - ADAP: PRECLINICAL TESTING RAISES NO SAFETY CONCERNS FOR MAGE A4

More notable recent Adaptimmune Therapeutics plc (NASDAQ:ADAP) news were published by: Seekingalpha.com which released: “Adaptimmune up 6% premarket on positive ADP-A2M4 data in cancer - Seeking Alpha” on May 06, 2019, also Globenewswire.com with their article: “Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting - GlobeNewswire” published on May 02, 2019, Finance.Yahoo.com published: “The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs - Yahoo Finance” on April 27, 2019. More interesting news about Adaptimmune Therapeutics plc (NASDAQ:ADAP) were released by: Nasdaq.com and their article: “European ADRs Move Lower in Tuesday Trading - Nasdaq” published on April 23, 2019 as well as Nasdaq.com‘s news article titled: “European ADRs Move Lower in Wednesday Trading - Nasdaq” with publication date: April 24, 2019.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. The company has market cap of $481.68 million. The Company’s platform enables to identify cancer targets; find and genetically engineer T-cell receptors ; and produce TCR therapeutic candidates for administration to patients. It currently has negative earnings. The company's lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma.

Analysts await Adaptimmune Therapeutics plc (NASDAQ:ADAP) to report earnings on May, 8. They expect $-0.32 earnings per share, down 33.33% or $0.08 from last year’s $-0.24 per share. After $-0.36 actual earnings per share reported by Adaptimmune Therapeutics plc for the previous quarter, Wall Street now forecasts -11.11% EPS growth.

Park West Asset Management Llc holds 6.11% of its portfolio in National General Holdings Corp. for 5.11 million shares. Msd Partners L.P. owns 2.16 million shares or 5.72% of their US portfolio. Moreover, Pembroke Management Ltd has 3.48% invested in the company for 1.05 million shares. The Texas-based Hillcrest Asset Management Llc has invested 2.27% in the stock. Philadelphia Financial Management Of San Francisco Llc, a California-based fund reported 449,324 shares.

Since January 1, 0001, it had 2 insider purchases, and 0 insider sales for $652,776 activity.

The stock decreased 1.29% or $0.32 during the last trading session, reaching $24.51. About 86,800 shares traded. National General Holdings Corp. (NGHC) has risen 15.03% since May 7, 2018 and is uptrending. It has outperformed by 10.66% the S&P500. Some Historical NGHC News: 21/04/2018 - Harun Maruf: BREAKING: Somali Defense Ministry officially takes over UAE-run training centre in Mogadishu. Deputy Commander of; 07/05/2018 - NATIONAL GENERAL HOLDINGS CORP - BOARD APPOINTED ROBERT KARFUNKEL AND BARRY KARFUNKEL TO SERVE AS CO-CHAIRMEN OF BOARD; 07/05/2018 - National General 1Q EPS 55c; 22/04/2018 - DJ National General Holdings Corp, Inst Holders, 1Q 2018 (NGHC); 07/05/2018 - NATIONAL GENERAL HOLDINGS CORP - QTRLY GROSS WRITTEN PREMIUM GREW $165.1 MLN OR 14.1% TO $1,337.0 MLN; 07/03/2018 - National General Company Marketing Set By FBR for Mar. 14-16; 14/03/2018 - National General at Company Marketing Hosted By FBR Today; 06/04/2018 - A.M. Best Affirms Credit Ratings of National General Insurance Company (P.S.C.); 05/03/2018 National General Forms Golden Cross: Technicals; 12/03/2018 - National General Non-Deal Roadshow Scheduled By KBW for Mar. 19

National General Holdings Corp. (NASDAQ:NGHC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.